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• Evaluate and describe current available literature on 
the use of heparin derivatives in overweight and 
obese pediatric patients 
• Assess efficacy and safety parameters of heparin 
derivatives in overweight and obese pediatric 
patients
• A comprehensive literature search of PubMed, 
SCOPUS, Cumulative Index of Nursing and Allied 
Health, Academic Search Complete, PsycInfo, 
Cochrane Library, and Web of Science databases was 
conducted.
• Search terms used were “LMWH OR low molecular 
weight heparin OR enoxaparin OR dalteparin OR 
tinzaparin OR fondaparinux,” AND “pediatric OR child 
OR children,” AND “obese OR obesity OR 
overweight.”
• No limits or timeline restrictions were imposed.
• Studies were included if they contained pediatric 
patients who were overweight or obese and received 
either enoxaparin, dalteparin, tinzaparin, or 
fondaparinux. 
• Exclusion criteria: Duplicate studies; off-topic studies; 
adult studies; inaccessible full articles; non-English 
studies; animal trials. 
• According to the CDC, one in five minors in the United 
States are described as obese.1
• Obese children are at higher risk of a hypercoagulable 
event, such as venous thromboembolism, compared 
to healthy weight children.2
• Concerns exist with the narrow therapeutic window 
of anticoagulants in general, and especially with 
children.3
• The use of low molecular weight heparins (LMWHs) in 
anticoagulation prophylaxis in overweight and obese 
children has been sparsely studied.
RESULTS
• Enoxaparin was the most studied heparin derivative in 
obese pediatric patients.
• Evidence for dalteparin and fondaparinux were limited; 
no studies using tinzaparin in this population were 
retrieved.
• Enoxaparin dose reductions of 13% to 37% occurred 
from baseline within the treatment studies.
• Prophylactic dose increases of enoxaparin from 
baseline ranged from 0% to 27.3%.
• Monitoring of anti-factor Xa measurements was 
inconsistently performed or reported by investigators.
• Fourteen minor bleeding events were reported in the 
literature along with one major bleeding event.
• Three thrombus extensions and two new thrombotic 
formations were described.
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• Enoxaparin is the most frequently described 
anticoagulant in the obese pediatric literature.
• Monitoring should be performed using anti-factor Xa 
measurements, although controversy does exist with 
the use of these measurements.
• Larger, long-term randomized controlled trials are 
needed to determine optimized treatment strategies 
on the heparin derivatives for better clinical outcomes 
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Figure 2: Changes in enoxaparin doses to reach 
therapeutic anti-factor Xa measurements
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DISCUSSIONRESULTS
• The observed decrease seen from the enoxaparin 
treatment studies suggests that obese pediatric 
patients may be receiving supratherapeutic dosing 
initially.
• Prophylactic doses of enoxaparin were unchanged in 
two of three studies regardless of monitoring due to 
study protocol.
• Minor bleeding events were the most commonly 
reported safety parameter, with only one incidence of a 
major bleed inferred in the literature.
• The observed lack of monitoring is concerning due to 
the narrow therapeutic window of these agents, 
potentially placing patients at greater risk for safety 
concerns.
• Presently, there is no sub-stratification of obesity in 
pediatric patients, which could have a dramatic 
influence on future dosing of heparin derivatives.
